MA49599B1 - Anticorps spécifiques à cd47 et pd-l1 - Google Patents

Anticorps spécifiques à cd47 et pd-l1

Info

Publication number
MA49599B1
MA49599B1 MA49599A MA49599A MA49599B1 MA 49599 B1 MA49599 B1 MA 49599B1 MA 49599 A MA49599 A MA 49599A MA 49599 A MA49599 A MA 49599A MA 49599 B1 MA49599 B1 MA 49599B1
Authority
MA
Morocco
Prior art keywords
antibodies
relates
antibodies specific
antigen
field
Prior art date
Application number
MA49599A
Other languages
English (en)
Other versions
MA49599A1 (fr
Inventor
Timofey Aleksandrovich Nemankin
Kirill Vladimirovich Solovyev
Andrei Borisovich Ulitin
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA49599A1 publication Critical patent/MA49599A1/fr
Publication of MA49599B1 publication Critical patent/MA49599B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne le domaine de la biotechnologie et notamment le domaine des anticorps ou leurs fragments de liaison d'antigènes ainsi que leur utilisation. Elle concerne plus particulièrement des anticorps qui se lient spécifiquement à cd47 et pd-l1. L'invention concerne également un acide nucléique codant pour cet anticorps ou son fragment de liaison d'antigènes, un vecteur d'expression, un procédé de production d'anticorps et l'utilisation de ces anticorps et composition dans la thérapie du cancer.
MA49599A 2017-10-03 2018-10-03 Anticorps spécifiques à cd47 et pd-l1 MA49599B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA201791961A EA039662B1 (ru) 2017-10-03 2017-10-03 Антитела, специфичные к cd47 и pd-l1
PCT/EA2018/050001 WO2019068302A1 (fr) 2017-10-03 2018-10-03 Anticorps spécifiques à cd47 et pd-l1

Publications (2)

Publication Number Publication Date
MA49599A1 MA49599A1 (fr) 2021-01-29
MA49599B1 true MA49599B1 (fr) 2023-05-31

Family

ID=65994976

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49599A MA49599B1 (fr) 2017-10-03 2018-10-03 Anticorps spécifiques à cd47 et pd-l1

Country Status (21)

Country Link
US (1) US11840567B2 (fr)
EP (1) EP3693390A4 (fr)
JP (2) JP2020535839A (fr)
KR (1) KR20200058542A (fr)
CN (1) CN111801352A (fr)
AR (1) AR113342A1 (fr)
AU (1) AU2018345458A1 (fr)
BR (1) BR112020006706A2 (fr)
CA (1) CA3078413A1 (fr)
CL (1) CL2020000919A1 (fr)
CO (1) CO2020004199A2 (fr)
EA (1) EA039662B1 (fr)
EC (1) ECSP20024555A (fr)
JO (1) JOP20200078A1 (fr)
MA (1) MA49599B1 (fr)
MX (1) MX2020004027A (fr)
PE (1) PE20210460A1 (fr)
PH (1) PH12020550214A1 (fr)
TW (1) TWI768129B (fr)
WO (1) WO2019068302A1 (fr)
ZA (1) ZA202002047B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2019000055A1 (en) 2016-09-29 2020-07-15 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs and preparation methods thereof
CN109963876B (zh) 2016-11-18 2023-11-14 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
MX2020005792A (es) * 2017-12-04 2020-11-06 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo anti-pd-l1/anti-cd47 biespecifico con estructura tipo anticuerpo natural y en forma de heterodimero y preparacion del mismo.
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
WO2019153200A1 (fr) 2018-02-08 2019-08-15 北京韩美药品有限公司 Anticorps bispécifique de type structure d'anticorps naturel anti-pd -1/anti-her2 sous forme hétérodimère et sa préparation
EP3564263A1 (fr) * 2018-05-03 2019-11-06 Universitätsklinikum Hamburg-Eppendorf Protéines de fusion comprenant un vhh spécifique de marqueur de surface cellulair
WO2020233539A1 (fr) * 2019-05-17 2020-11-26 Nanjing GenScript Biotech Co., Ltd. Protéines liant plusieurs antigènes anti-cd47/anti-pd-l1 et procédés d'utilisation associés
CN114040777A (zh) * 2019-06-25 2022-02-11 信达生物制药(苏州)有限公司 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途
EP3998287A4 (fr) * 2019-07-08 2023-08-09 Nanjing GenScript Biotech Co., Ltd. Anticorps bispécifique anti-cd47/anti-pd-1, son procédé de préparation et son utilisation
US20230340157A1 (en) * 2019-09-27 2023-10-26 Beijing Starmab Biomed Technology Ltd Monospecific and multi-specific antibodies
CN112745392B (zh) * 2019-10-30 2022-07-01 上海洛启生物医药技术有限公司 抗pd-l1/cd47双特异性抗体及其用途
EP4077387A1 (fr) 2019-12-17 2022-10-26 Pfizer Inc. Anticorps spécifiques pour cd47, pd-l1, et leurs utilisations
CA3167352A1 (fr) * 2020-02-12 2021-08-19 Xiangyu He Anticorps a unique domaine ciblant cd47 humain et son utilisation
WO2022057939A1 (fr) * 2020-09-21 2022-03-24 I-Mab Biopharma Co., Ltd. Composition pharmaceutique comprenant un anticorps cd47 et un inhibiteur de pd-1/pd-l1
CN114437227A (zh) * 2020-11-06 2022-05-06 百奥泰生物制药股份有限公司 双特异抗体及其应用
CN114478770A (zh) * 2020-11-12 2022-05-13 迈威(上海)生物科技股份有限公司 抗体及其制备方法
KR20220118963A (ko) * 2021-02-19 2022-08-26 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
AU2022222423A1 (en) * 2021-02-19 2023-09-28 Seoul National University R&Db Foundation Single domain antibody against pd-l1 and use thereof
MX2023009717A (es) * 2021-02-19 2024-01-08 Shaperon Inc Anticuerpo de dominio individual contra cúmulo de diferenciación 47 (cd47) y uso del mismo.
AU2022270543A1 (en) * 2021-05-07 2023-11-30 Immuneoncia Therapeutics, Inc. Bispecific antibody specifically binding to cd47 and pd-l1
MX2024000266A (es) * 2021-06-21 2024-01-31 Biocad Joint Stock Co Anticuerpo biespecifico aislado que se une especificamente a cd47 y pd-l1.
CN115702931A (zh) * 2021-08-06 2023-02-17 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在治疗疾病中的应用
CN118076644A (zh) * 2021-09-30 2024-05-24 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体
WO2023154730A2 (fr) * 2022-02-09 2023-08-17 Exelixis, Inc. Agents de liaison multispécifiques et leurs utilisations
WO2023224412A1 (fr) * 2022-05-19 2023-11-23 (주)샤페론 Anticorps bispécifique à domaine unique humanisé dirigé contre pd-l1 et cd47 et son utilisation
WO2024022384A1 (fr) * 2022-07-28 2024-02-01 Shenzhen Enduring Biotech , Ltd. Conjugué anticorps-médicament bispécifique anti-cd47/anti-pd-l1 à base de peg
CN118255894A (zh) * 2022-12-27 2024-06-28 广东菲鹏制药股份有限公司 一种双特异性结合分子及其应用
CN116063526A (zh) * 2022-12-31 2023-05-05 合肥天港免疫药物有限公司 抗pdl1的抗体及其用途
WO2024146539A1 (fr) * 2023-01-04 2024-07-11 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps bispécifiques dirigés contre pd-l1 et cd47, leur procédé de préparation et leur utilisation

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
EP0625200B1 (fr) 1992-02-06 2005-05-11 Chiron Corporation Proteine de liaison biosynthetique pour marqueur de cancer
EP0656064B1 (fr) 1992-08-17 1997-03-05 Genentech, Inc. Immunoadhesines bispecifiques
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2226962A1 (fr) 1998-02-16 1999-08-16 Marie Sarfati Utilisation d'agents liants a cd47 et ces ligands pour le traitement ou prophylaxie de maladies inflammatoire, autoimmunitaire et allergique et pour le traitement de rejet de greffons
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
JP2004535542A (ja) 2000-08-18 2004-11-25 リンデ　アクチエンゲゼルシヤフト 空気分離設備の製造法
WO2002086083A2 (fr) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Procedes d'amelioration de la capacite de reaction de cellules t
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2009114335A2 (fr) * 2008-03-12 2009-09-17 Merck & Co., Inc. Protéines de liaison avec pd-1
CA2998281C (fr) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Anticorps anti-pd-1 humains et leurs utilisations
EP4169951A1 (fr) 2008-12-09 2023-04-26 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
PE20141908A1 (es) 2012-02-06 2014-12-21 Inhibrx Llc Anticuerpos cd47 y metodos de uso los mismos
CA2892585C (fr) 2012-12-03 2022-07-05 Novimmune S.A. Anticorps anti-cd47 et leurs procedes d'utilisation
EP2931751B1 (fr) 2012-12-12 2020-02-05 Arch Oncology, Inc. Anticorps anti-cd47 thérapeutiques
GB201300706D0 (en) 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
KR102170196B1 (ko) 2013-02-06 2020-10-26 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
WO2016023001A1 (fr) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Agents pd-1 à haute affinité multispécifiques et procédés d'utilisation
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
CN108290948B (zh) 2015-09-21 2021-10-29 伊拉兹马斯大学医疗中心 抗-cd47抗体及使用方法
RU2665790C1 (ru) * 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1

Also Published As

Publication number Publication date
JOP20200078A1 (ar) 2020-04-30
JP2023130455A (ja) 2023-09-20
WO2019068302A1 (fr) 2019-04-11
RU2020115122A (ru) 2021-10-29
ZA202002047B (en) 2022-08-31
MX2020004027A (es) 2020-08-13
RU2020115122A3 (fr) 2021-10-29
CN111801352A (zh) 2020-10-20
TWI768129B (zh) 2022-06-21
US11840567B2 (en) 2023-12-12
CO2020004199A2 (es) 2020-04-24
PH12020550214A1 (en) 2021-02-15
EA201791961A1 (ru) 2019-04-30
MA49599A1 (fr) 2021-01-29
JP2020535839A (ja) 2020-12-10
EP3693390A4 (fr) 2021-11-03
CA3078413A1 (fr) 2019-04-11
KR20200058542A (ko) 2020-05-27
EA039662B1 (ru) 2022-02-24
AU2018345458A2 (en) 2020-05-21
PE20210460A1 (es) 2021-03-08
CL2020000919A1 (es) 2020-10-16
US20200270345A1 (en) 2020-08-27
BR112020006706A2 (pt) 2020-10-06
AR113342A1 (es) 2020-04-22
ECSP20024555A (es) 2020-06-30
EP3693390A1 (fr) 2020-08-12
AU2018345458A1 (en) 2020-05-14
TW201922781A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
MA44547A1 (fr) Anticorps anti-pd-1,procédé de leur production et de leur utilisation
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MX2009006891A (es) Anticuerpos cd44.
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MA54969A1 (fr) Anticorps monoclonal se liant spécifiquement à gitr
AU2017236063A1 (en) Monoclonal antibodies against the active site of factor XI and uses thereof
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
WO2021227307A8 (fr) Anticorps anti-cd73 et son utilisation
MA39378A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
MA45831B1 (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation
JOP20210159A1 (ar) أجسام مضادة لـ pmel17 ومترافقات منها
MA44207B1 (fr) Immunoglobulines conjuguées cys80
MA49607A1 (fr) Anticorps monoclonal pour il-5ra
EA202092672A1 (ru) Антитела против dll3 и их применения
EA202092981A1 (ru) Антитела к l1cam и их применение
MA41666B1 (fr) Anticorps anti-ox40 et leurs utilisations
MA40086A1 (fr) Anticorps anti-vasa et leurs procédés de production et d'utilisation